Table 3.

Association of markers of PI3K/AKT/mTOR pathway activity with clinical outcome

Basal biomarker	n (%)	DCR at 12 weeks (%)	P value	Median PFS (95% CI), months	P value	Median OS (95% CI), months	P value
p-S6 Ser 235/236
Low	14 (67)	6 (43)	0.659	3.0 (1.4–12.7)	0.792	8.5 (2.5–16.6)	0.281
High	7 (33)	4 (57)		6.0 (1.1–NR)		9.5 (1.1–20.5)
p-S6 Ser 240/244
Low	13 (62)	7 (54)	0.659	5.8 (1.4–12.7)	0.471	14.4 (2.47–18.6)	0.378
High	8 (38)	3 (37)		3.0 (1.1–NR)		6.6 (1.09–16.6)
p-mTOR
Low	15 (68)	6 (40)	0.685	5.5 (1.4–12.7)	0.295	9.5 (5.5–16.6)	0.851
High	7 (32)	3 (43)		2.5 (1.1–8.4)		6.7 (1.1–17.1)
p-AKT Ser 473
Low	14 (67)	7 (50)	1	5.5 (1.4–11.2)	0.409	8.1 (1.81–16.6)	0.853
High	7 (33)	3 (43)		6.0 (1.41–NR)		9.5 (4.38–19.6)
p-4EBP1
Low	13 (62)	8 (61)	0.183	6.0 (1.4–16.8)	0.143	14.4 (2.5–19.9)	0.052
High	8 (38)	2 (25)		2.6 (1.09–NR)		6.6 (1.09–16.5)
PTEN
Low	5 (24)	3 (60)	0.635	7.1 (2.8–NR)	0.844	16.6 (5.6–NR)	0.621
High	16 (76)	7 (44)		5.5 (1.4–16.8)		7.2 (2.5–17.1)

CI confidence interval, NR not reached